Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis

By sjmartinez • July 24, 2024

Karpouzas GA, Ormseth SR, van Riel PLCM, Gonzalez-Gay MA, Corrales A, Rantapää-Dahlqvist S, Sfikakis PP, Dessein P, Tsang L, Hitchon C, El-Gabalawy H, Pascual-Ramos V, Contreras-Yáñez I, Colunga-Pedraza IJ, Galarza-Delgado DA, Azpiri-Lopez JR, Semb AG, Misra DP, Hauge EM, Kitas G. Biological use influences the impact of inflammation on risk of major adverse cardiovascular events in rheumatoid arthritis. RMD Open. 2024 Jul 23;10(3):e004546. doi: 10.1136/rmdopen-2024-004546. PMID: 39043615.

Tags: Arthritis, biological therapy, cardiovascular diseases, Harbor UCLA, Inflammation, Publications, Rheumatoid, Rheumatology

Doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin lymphoma: Real-world experience from a Los Angeles County hospital

Chao E, Marshalek JP, Yashar D, Tomassetti S. Doxorubicin, bleomycin, vinblastine, and dacarbazine for Hodgkin lymphoma: Real-world experience from a Los Angeles County hospital. SAGE[...]

Understanding the Determinants of Decision Readiness in Kidney Replacement Therapy: Shared Decision Making, Health Literacy, and Population-Health Strategies

Kalantar-Zadeh K, Zisman-Ilani Y. Understanding the Determinants of Decision Readiness in Kidney Replacement Therapy: Shared Decision Making, Health Literacy, and Population-Health Strategies. Clin J Am[...]

Racial and Ethnic Disparities in Outcomes following Preemptive Kidney Transplant Waitlisting in the United States from 2009-2024

Adeyemo S, Crews DC, Lentine KL, Zisman-Ilani Y, Lincoln K, Flores GM, Bunnapradist S, Ferrey AJ, Reddy UG, Muzaale AD, Rule AD, Saunders M, Garg[...]